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Background: Acute myocardial infarction (AMI) is one of the leading causes for death in both developed and
developing countries and it is the single largest cause of death in the United States, responsible for 1 out of every 6
deaths. The objective of this study was to determine microRNA (miRNA) expression in AMI and determine whether
miR-133, miR-1291 and miR-663b could be measured in plasma as a biomarker for recurrence.
Methods: Patients with AMI and those without AMI were retrospectively recruited for a comparison of their plasma
miR-133, miR-1291 and miR-663b expression.
Results: miR-133, miR-1291 and miR-663b levels were significantly overexpressed in AMI compared with Non-AMI.
MiR-133 showed an AUC of 0.912, with a sensitivity of 81.1% and a specificity of 91.2%. The AUC for miR-1291 was
0.695, with a sensitivity of 78.4% and a specificity of 89.5%. The AUC for miR-663b was 0.611, with a sensitivity of
72.4% and a specificity of 76.5%.
Conclusions: This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI.
The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as
circulating biomarkers for the AMI progonos warrants further study.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8183629061241474
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Acute coronary syndrome (ACS) is a very common health
problem in the all the world. Acute myocardial infarction
(AMI) is one of the leading causes for death in both devel-
oped and developing countries and it is the single largest
cause of death in the United States, responsible for 1 out
of every 6 deaths [1]. Up to 10 million Americans report
to an Emergency Department (ED) for chest pain yearly
and this number is expected to climb with continued
aging of the United States (U.S.) population [2]. The sub-
stantial number of emergent hospitalizations for ACS, in-
cluding ST-elevation myocardial infarction (STEMI), Non* Correspondence: mdqcg09@163.com
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unless otherwise stated.ST-elevation myocardial infarction (NSTEMI), and un-
stable angina (UA), represents a significant financial strain
to both patients and the healthcare system [3]. This bur-
den could be ameliorated, and more efficient treatment
administered, if a more rapid, sensitive, and specific bio-
marker could differentiate between the spectrum of ACS
(i.e. STEMI, NSTEMI, and UA) as well as differentiate
from other less concerning causes of chest pain, such as
gastroesophageal reflux (GERD). Rapid and correct diag-
nosis of AMI plays an important role in therapy and prog-
nosis for this disease [4]. Over the past two decades, huge
progress has been made in the diagnosis, treatment, and
prognosis of AMI. Particularly, the progress in biomarkers
for AMI attracted a great deal of attention. Currently,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.diagnosticpathology.org/content/9/1/89cardiac troponins are the most common biomarkers used
for diagnosis of AMI in clinical practice [5]. However, there
is still a clinical need for novel biomarker, which is able to
reliably rule in or rule out AMI immediately on admission.
MicroRNAs (miRNAs) are small (19-22-nt) single stranded
non-coding RNA molecules that are derived from
hairpin-structured precursors [6,7]. These microRNAs
function by directly binding to heir potential target site
in the 3′ untranslated region (3′ UTRs) of specific target
mRNA, leading to the repression of mRNA translation
or the degradation of target mRNAs. Small non-coding
RNAs were also recently implicated in control of DNA
damage response. Currently, there are 24521 mature
miRNA sequences of both human and other species
listed in the miRNA registry (Sanger miRBase; http://
www.mirbase.org/). Over recent years, many miRNAs have
been investigated in various human disease, such as kinds
of cancer and cardiovascular diseases [7,8]. The deregula-
tion of expression of microRNAs has been shown to con-
tribute to the multistep processes of carcinogenesis in
human by modification either of oncogenic or suppressor
gene function [9]. Nowadays, microRNA expression pat-
terns are known to characterize the developmental origins
of tumors more effectively than mRNA expression signa-
tures and thus can be a useful tool for the diagnosis and
prognosis of human disease [9]. It has long been a goal of
cardiovascular research to search for non-invasive tools for
the diagnosis and management of AMI that can greatly re-
duce its worldwide health burden [10]. Recently, it has been
reported that microRNAs are circulating in serum/plasma
and AMI related microRNAs such as miR-1, miR-133a,
miR-208b, miR-223, miR-320a, miR-451 and miR-499 have
been detected in the plasma or serum of AMI patients
[11,12]. These circulating microRNAs can be consid-
ered as a new class of effective biomarkers where their
abundance profile might reflect physiological and/or patho-
logical conditions. Accordingly, several subsequent studies
have proven that miRNAs can serve as potential bio-
markers for various cardiovascular diseases, such as AMI.
The purpose of the present study was to characterize
the levels of miRNAs including miR-133, miR-1291 and
miR-663b in the circulation of AMI patients. Accordingly,
an extensive detection of miRNAs was screened for in the
AMI patients and the results were compared with an age-,
gender-, and ethnically matched control group. We aimed




The study was approved by First affiliated Hospital of
Zhengzhou University. Written informed consent was
obtained for the acquisition and use of patient tissue
samples and anonymized clinical data.Patient and control cohorts
All patients presenting with suspected AMI pain in the cor-
onary care unit at the First affiliated Hospital of Zhengzhou
University from Jan 2008 to Jan 2009, were offered to take
part in the study. Among 397 AMI cases, 205 cases were
included in this study. See Table 1 for patient characteris-
tics. ST-elevation myocardial infarction (STEMI) diagnosis
was based on ECG criteria, non-STEMI (NSTEMI) on
troponin levels together with clinical symptoms of ische-
mia. Non-MI was defined as absence of troponin-elevation
and absence of ST-elevation. A peripheral venous blood
sample was drawn into tubes containing EDTA, plasma
was prepared as described above and stored in liquid nitro-
gen until analyzed. 71% of blood samples were taken within
24 hours, 82% within 48 hours and 93% within 72 -hours.
In 90% of the patients, samples were obtained after inter-
ventional therapy. 95% of patients were treated with per-
cutaneous coronary intervention (PCI). Left ventricular
ejection fraction (LVEF) was assessed with echocardiog-
raphy before discharge. Samples were taken at admission,
at 3, 10 and 20 hours. Daily repeated samples were taken
until a peak value had been identified. The disease and
personal history were obtained from the patient and previ-
ous data. A total of 25 patient diagnoses as STEMI receive
an emergency PCI. The post-operative peripheral venous
blood sample was drawn into tubes containing EDTA.
Plasma samples
Venous blood was drawn from each patient both on the
day of surgery before commencement of the procedure and
between 2 and 6 weeks after surgery. Blood was drawn with
the Vaccutainer venepuncture system into ethylene diamine
tetraacetic acid (EDTA) tubes (Becton, Dickinson and
Company, Melbourne, Australia). The first 3 mL were dis-
carded to avoid possible contamination with miRNAs of
the skin plug from the puncture. The blood was then cen-
trifuged at 3800 g for 15 minutes. A maximum of 4 hours
between the blood draw and separation into plasma was
the standardized protocol in this study, although it has been
reported that miRNAs are stable for up to 24 hours of incu-
bation at room temperature. The supernatant (plasma) was
separated from the cellular layer by pipetting, and the 3 to
5 mm of plasma just above the interphase was sacrificed to
prevent disturbance of the cellular layer. The plasma was
stored at 280°C until RNA extraction.
RNA extraction
Total RNA was extracted from 200lL of thawed plasma
with the miRNeasy Mini Kit (Qiagen), in accordance with
the manufacturer’s instructions. The RNA was eluted with
50 mL of RNAse-free water and was stored at −70°C until
RT-PCR reaction. We quantified the concentration of all
RNA samples using NanoDrop 1000 (Thermo Scientific,
Wilmington, DE, USA).
Table 1 Clinical characters, risk factor and symptoms of the cohort
Clinicopathological features All cohort (n = 186) AMI cases P
Yes (n = 76) No (n = 110)
Age (year) 62.2 (46–88) 64.6 (46–88) 60 (52–81) 0.071
Male 104 43 61 0.282
BMI 27.2 (23–34) 26.9 (24–34) 27.5 (23–32) 0.455
STEMI 25
NSTEMI 51
Disease and personal history
Hypertension 122 74 48 0.341
Hypercholesterolemia 104 54 50 0.033
Diabetes 88 43 45 0.237
Smoking 104 42 62 0.569
Alcohol drinking 92 36 56 0.382
Previous AMI 34 19 15 0.020
Previous PTCA 25 15 10 0.001
Physical examination
Systolic blood pressure, mmHg 138 (121–185) 139 (121–179) 141 (127–185) 0.875
Diastolic blood pressure, mmHg 83 (72–103) 83 (75–99) 84 (72–103) 0.531
Heart rate – beats per minute 75 (62–145) 79 (67–145) 73 (62–91) 0.129
Electrocardiographic findings
T-wave inversion 25 21 4 < 0.001
ST-segment change 46 36 10 < 0.001
Other Changes 18 9 9 < 0.001
No significant changes 97 10 87 < 0.001
BMI: body mass index; AMI: acute myocardial infarction; STEMI: ST-segment-elevation; NSTEMI: non-ST-segment elevation; PTCA, Percutaneous transluminal
coronary angioplasty.
The results with a significant difference were marked in bold.
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chain reaction
The expression levels of individual miRNAs were mea-
sured with quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) using TaqMan miRNA assays
(Applied Biosystems, Foster City, Calif). The relative
expression (RQ) was obtained using the ΔΔCt method.
Briefly, total RNA was reverse transcribed to complemen-
tary DNA (cDNA) using TaqMan miRNA primers accord-
ing to the manufacturer’s instructions. The PCR products
were then amplified from cDNA using the TaqMan
miRNA probes with the ABI 7900HT Real-time PCR Sys-
tem according to the manufacturer’s instructions. Stand-
ard TaqMan miRNA cycling conditions were used, and all
samples were run in triplicate. The miR-16 was used as an
endogenous control for the plasma samples. All samples
across all PCR plates were calibrated against commercially
available human thyroid total RNA (Ambion; Life Tech-
nologies Corporation, Carlsbad, Calif ).
In the present study, expression of the target miRNAs in
plasma was normalized relative to the expression of the en-
dogenous control miR-16. Data were analyzed by the ΔCtmethod: ΔCt =Ct value (miR-16) - Ct value (miRNA of interest).
All data were represented by 2-△Ct value.
Statistical analysis
Differences between groups were assessed by Mann–
Whitney U-test, Fisher’s exact test, or chisquare-test,
and Steel–Dwass test was performed for multiple com-
parisons. Paired samples were analyzed by Wilcoxon’s
single-rank test. The diagnostic value for differentiating
between BTC patients and the control was assessed by
calculating the area under the receiver-operator charac-
teristic curve (AUC). Validation of ROC results was per-
formed by the leave-one-out cross-validation method as
described before. In the validation, first, by using the
subset of all but one sample, we built a ROC model, and
defined the cut-off value in such a way that the sum of
sensitivity and specificity was maximized. Then, using
the cut-off value, the model was used to predict the left-
out recorded samples. When this process was repeated
for each sample, the prediction was obtained for every
record in the dataset using a model that was blind to
the predicted observation. All statistical analyses were
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Chicago, IL). A P-value of < 0.05 denoted the presence
of a statistically significant difference.
Results
Patient characteristics
The baseline characteristics of the patients in this study
are listed in Table 1. The median age of the all the pa-
tients with was 62.2 years (range, 46–88 years) in the
whole cohort, 64.6 years (46–88) in AMI group and
60 years (range, 52–81 years) in the non-AMI group. In
the AMI group, there were 25 cases with STEMI and 51
cases with NSTEMI.
When the disease and personal history were considered,
there were no significant differences in the status of hyper-
tension, diabetes, smoking and alcohol drinking status in
the AMI and non-AMI group. However, the rate of hyper-
cholesterolemia was more common in the AMI group
(P = 0.033). The history AMI and PTCA was assessed in
both groups and the incidence of there two status were
more common in the AMI group (P = 0.020 and P = 0.001).
The physical examination showed that no significant
differences were observed in the systolic blood pressure,
diastolic blood pressure and heart rate between the two
groups. However, an advanced study of the electrocar-
diographic findings showed that the rates of T-wave in-
version, ST-segment change and other changes were
higher in the AMI group (P < 0.001).
MiR-133, miR-1291 and miR-663b expression in
the cohort
The three miRNAs expression was detected in 76 AMI
cases (25 STEMI cases and NSTEMI cases) and 110
non-AMI controls normalized to miR-16. As shown in
Figure 1, we found that the expression of miR-133 was
distinctly increased in STEMI (mean ± SD: 7.6 ± 1.8) and
NSTEMI cases (mean ± SD: 7.1 ± 2.8) compared to non-
AMI cases (mean ± SD: 3.1 ± 1.3, P < 0.001). In addition,
miR-1291 expression in NSTEMI (mean ± SD: 3.3 ± 0.9)Figure 1 Levels of the three miRNAs (A: miR-133; B: miR-1291 and C:
P-values describe the significance level of differences for each miRNA betw
STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segmenwas higher than the non-AMI group (mean ± SD: 1.6 ±
1.4, P < 0.01); however, no significant difference was de-
tected in the STEMI group (mean ± SD: 1.8 ± 2.1) com-
pared with the control group (P = 0.06). MiR-663b was
distinctly increased in STEMI (mean ± SD: 3.3 ± 1.6) and
NSTEMI cases (mean ± SD: 1.4 ± 1.4) compared to non-
AMI cases (mean ± SD: 1.0 ± 1.2, P < 0.001).
Diagnostic performance of miR-133, miR-1291, and
miR-663b
The diagnostic performances of miR-133, miR-1291, and
miR-663b for the AMI were detected. Cut-off points were
determined using the highest sum of sensitivity and speci-
ficity. The cut-off points for miR-133, miR-1291, and miR-
663b were 4.12, 1.97, and 1.26 respectively. MiR-133
showed an AUC of 0.912, with a sensitivity of 81.1% and a
specificity of 91.2% (Figure 2A). The AUC for miR-1291
was 0.695, with a sensitivity of 78.4% and a specificity of
89.5% (Figure 2B). The AUC for miR-663b was 0.611, with
a sensitivity of 72.4% and a specificity of 76.5% (Figure 2C).The change of the expression after the surgery
A total of 25 STEMI cases were obtained to detect the
change of the three miRNAs. Compared with the pre-
operative expression, all the three miRNAs demonstrated
a significant depression. As showed in Figure 3, the ex-
pression of miR-133 changed from 7.6 to 4.3 (P = 0.012).
Before the surgery, the expression of miR-1291 was 3.3 ±
0.9 while the post-operative level is 2.1 (P = 0.041). The
level of miR-663b changed from 3.3 to 1.2 and a signifi-
cant difference was detected (P = 0.032).Discussion
There is a growing requirement for the detection of a
new tool for the AMI. MicroRNAs are small molecules
approximately 22 nucleotides in length and have been
well conserved evolutionally. Although they are noncod-
ing genes, they are involved in the regulation of a widemiR-663b) at presentation in patients with without (n = 931) AMI.
een patients with and without AMI. AMI, acute myocardial infarction;
t elevation myocardial infarction.
Figure 2 Receiver operating characteristic curves for the diagnostic accuracy for the three miRNAs. (A) miR-133, (B) miR-1291, (C) miR-663b.
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http://www.diagnosticpathology.org/content/9/1/89range of biologic processes through translational modula-
tion. In cardiovascular pathology, they have been used to
classify heart failure and hypertension [13,14]. As well, it
was also suggested that miRNA might be a potential bio-
marker for the diagnosis and prognosis of AMI [12]. In
this study, we initially identified the potential biomarker
for the diagnosis of AMI. By using qRT-PCR, we con-
firmed that miR-133, miR-1291 and miR-663b levels
were significantly overexpressed in AMI compared with
Non-AMI. Although the ROC analyses, we found that
there three miRNAs might be potential diagnostic
markers for the AMI. Besides, we found that the three
miRNAs were significantly decreased post-operatively
and which provided a suggestion of the prognosis value
for there miRNAs.
MiRNAs have recently been detected in serum or
plasma, which are referred to circulating miRNAs [15].
Despite intense research, the origin of circulating miR-
NAs remains largely unknown. A number of studies
have reported that miRNAs are actively secreted in
microvesicles or exosomes from different cell types,
which area likely source of circulating miRNAs. So far,
around 121 miRNAs were identified in exosomes fromFigure 3 The change of the expression before and after the surgery.mast cells, and sphingomyelinase 2 (nSMase2), a rate-
limiting enzyme for ceramide biosynthesis, controls the
secretion of exosomes to the extracellular matrix [16]. In
addition to microvesicles or exosomes, microparticles
and lipoprotein complexes (such as high-density lipopro-
tein complexes) are other possible sources of circulating
miRNAs Human miRNAs isolated from plasma are
highly stable in boiling water, in solution with very high
or low pH [17]. Plasma miRNA levels remain stable
when it is subjected to prolonged room temperature in-
cubation or freeze-thawed multiple times. It has been re-
ported that endogenous plasma miRNAs exist in a form
that is resistant to plasma Rnase activit. Compared to
the endogenous plasma miRNAs, rapid degradation was
observed within minutes when synthetic miRNAs (corre-
sponding to caenorhabditis elegans miRNAs cel-miR-39,
cel-miR-54, and cel-miR-238) were added into human
plasma.
Rapid and correct diagnosis is crucial to treatment and
prognosis of AMI. Up to date, cardiac troponins and
creatine kinase-MB are the most commonly used bio-
markers for AMI, but their clinical value is limited in
many cases. Secreted by cardiac cells and accumulated(A) miR-133, (B) miR-1291, (C) miR-663b.
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in response to cardiovascular risk factors and various
pathological conditions. Thus, the circulating cardiac-
specific or -enriched miRNAs (such as miR-208, miR-
499, and miR-133) may provide unique biomarkers for
diagnostic and therapeutic interventions of AMI [18].
MiRNA profiling studies in AMI and other diseases have
been vastly reported. For instance, a recent tissue
miRNA profiling study by Kuwabara Y et al. alrevealed
that serum levels of miR-1 and miR-133a were increased
significantly in patients not only with acute myocardial
infarction but also with unstable angina pectoris and
Takotsubo cardiomyopathy without elevation of serum
creatine phosphokinase or cardiac troponin [19]. An in-
vestigation by By Wang GK, through verifying their tis-
sue expression patterns with real-time PCR analysis,
muscle-enriched miRNAs (miR-1, miR-133a, and miR-
499) and cardiac-specific miR-208a were selected as candi-
dates for this study. With miRNA microarray and real-
time PCR analyses, miR-1, miR-133a, and miR-499 were
present with very low abundance, and miR-208a was
absent in the plasma from healthy people. In the AMI
rats, the plasma levels of these miRNAs were signifi-
cantly increased [20]. In a microarray study by periph-
eral total blood samples, identified 121 miRNAs, which
are significantly dysregulated in AMI patients in com-
parison to healthy controls. Among these, miR-1291
and miR-663b show the highest sensitivity and specifi-
city for the discrimination of cases from controls.
Using a novel self-learning pattern recognition algo-
rithm, we identified a unique signature of 20 miRNAs
that predicts AMI with even higher power (specificity
96%, sensitivity 90%, and accuracy 93%). In addition,
we show that miR-30c and miR-145 levels correlate
with infarct sizes estimated by Troponin T release [21].
Besides, in this study, we found that the expression
of miR-133, miR-1291 and miR-663b were significantly
reduced after the surgery. These findings were first re-
ported in this study. The reduction of these miRNAs
might indicate a sign of reconditioning of ischemic car-
diac muscle. The dynamic expression of these molecu-
lar biomarkers may be used as a prognostic marker.
Advanced well-designed studies with larger cohort and
longer follow-up are required.Conclusion
In this study, we identified plasma miR-133, miR-1291 and
and miR-663b were significantly increased in the AMI
cases. Through ROC analyses, it was found that miR-133,
miR-1291 and and miR-663b were potential predictors of
AMI. Circulating levels of the same miRNAs also were cor-
related with the presence of AMI. Advanced well-designed
studies are required.Competing interests
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